The demand for Lipid-Lowering Agents in Albania has been on the rise in recent years.
Customer preferences: Albanian consumers are becoming increasingly health-conscious and are looking for ways to manage their cholesterol levels. This has led to a growing demand for Lipid-Lowering Agents, which help to reduce cholesterol levels in the blood. Patients are also becoming more aware of the benefits of early intervention in the prevention of heart disease, which is a leading cause of death in Albania.
Trends in the market: The Lipid-Lowering Agents market in Albania is expected to grow steadily over the coming years. This is due to an aging population and an increasing prevalence of lifestyle-related diseases such as obesity and diabetes. The market is also being driven by the introduction of new drugs and the expansion of the healthcare sector in the country. However, the market is still relatively small compared to other European countries, and there is room for further growth.
Local special circumstances: One of the unique characteristics of the Albanian market is the dominance of generic drugs. This is due to the relatively low purchasing power of the population, which has led to a preference for cheaper alternatives. However, there is a growing trend towards the use of branded drugs, which are perceived to be of higher quality and more effective. This trend is likely to continue as the healthcare sector in Albania continues to develop.
Underlying macroeconomic factors: The Albanian economy has been growing steadily in recent years, which has led to an increase in disposable income and a growing middle class. This has had a positive impact on the healthcare sector, as more people are able to afford medical treatment and drugs. The government has also been investing in the healthcare sector, which has led to improvements in infrastructure and the quality of healthcare services. However, there are still challenges facing the healthcare sector, such as a shortage of medical professionals and outdated equipment.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
